ref-id,title,url,parent_key
F2122,Rituxan FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/122/original/Rituxan_FDA_label.pdf?1543612957,BE0000066
F714,EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/714/original/nivestim_EMA.pdf?1532118975,BE0000793
F719,TBO filgrastim,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/719/original/TBO_filgrastim.pdf?1532124628,BE0000793
F3151,Valsartan HCT monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/151/original/Valsartan_HCT_TAB_Monograph.pdf?1548441492,BE0000062
F3202,Protonix delayed release and oral suspension FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/202/original/Protonix_Delayed_relase_and_ora_susp.pdf?1548780962,BE0000349
F3286,Citalopram MedSafe NZ Data Sheet,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/286/original/ArrowCitalopramtab.pdf?1549058639,BE0000442
F3088,Canesten Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/088/original/Canesten_Monograph.pdf?1548281505,BE0004803
F3100,"MedSafe NZ Data Sheet, Clotrimazole",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/100/original/MedSafe_NZ_Data_Sheet-_Clotrimazole.pdf?1548285796,BE0004803
F3385,Requip FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/385/original/FDA_label__Requip.pdf?1549491148,BE0000756
F3439,"FDA label, Viread",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/439/original/viread-epar-product-information_en.pdf?1549650316,BE0004136
F3439,"FDA label, Viread",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/439/original/viread-epar-product-information_en.pdf?1549650316,BE0000312
F4142,"Data sheet, Acetaminophen, ebi.ac.uk",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/142/original/Data_sheet__Acetaminophen__ebi.ac.uk.pdf?1553717784,BE0002480
F3676,Codeine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/676/original/Codeine_FDA_label.pdf?1551131944,BE0000770
F3658,"EPAR, Codeine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/658/original/EPAR__Codeine.pdf?1551126557,BE0000770
F3463,Elavil Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/463/original/ELAVIL_PM.pdf?1549915886,BE0000486
F3466,Elavil Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/466/original/ELAVIL_PM.pdf?1549916327,BE0000749
F4685,FDA Label - Methadone,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/685/original/FDA_Label_-_methadone.pdf?1566927671,BE0004956
F3712,"FDA label, Omeprazole",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/712/original/Prilosec_FDA.pdf?1551285648,BE0000349
F3646,Cetirizine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/646/original/Cetirizine_FDA_label.pdf?1550872110,BE0000442
F4594,Remeron tablets FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/594/original/Remeron_tablets__FDA_label.pdf?1556741198,BE0000451
F4594,Remeron tablets FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/594/original/Remeron_tablets__FDA_label.pdf?1556741198,BE0000289
F4594,Remeron tablets FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/594/original/Remeron_tablets__FDA_label.pdf?1556741198,BE0000533
F4594,Remeron tablets FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/594/original/Remeron_tablets__FDA_label.pdf?1556741198,BE0000442
F4594,Remeron tablets FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/594/original/Remeron_tablets__FDA_label.pdf?1556741198,BE0004863
F3781,Identification of New Functional Inhibitors of Acid Sphingomyelinase Using a Structure-Property-Activity Relation Model,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/781/original/5642a377778bc6d0e3785f4d212a143096b1.pdf?1551735370,BE0000973
F3982,"FDA label, Allopurinol",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/982/original/Allopurinol_FDA_label.pdf?1552949475,BE0002204
F4244,Prazosin FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/244/original/Prazosin_FDA_label.pdf?1554399117,BE0004863
F1954,"Amikacin, DailyMed",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/954/original/20180501_f260ff2a-76a0-4672-9516-91c344b67890.pdf?1540315949,BE0000279
F1949,MedSafe NZ: Amikacin Injection,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/949/original/Amikacininj._MedSafe_NZ.pdf?1540245431,BE0000279
F3955,"Drug information, Valacyclovir",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/955/original/Drug_Information__Valacyclovir.pdf?1552923451,BE0000308
F3958,Valtrex FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/958/original/FDA_label__Valacyclovir.pdf?1552923741,BE0000308
F3961,"FDA label, Valtrex",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/961/original/FDA_label__Valacyclovir.pdf?1552925264,BE0000458
F3949,"Valtrex tablets, MedSafe NZ",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/949/original/Valtrex_MedSafe_NZ.pdf?1552685757,BE0000458
F1957,Retisert (Fluocinolone acetate) FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/957/original/fda.pdf?1540331588,BE0000422
F1957,Retisert (Fluocinolone acetate) FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/957/original/fda.pdf?1540331588,BE0001170
F1957,Retisert (Fluocinolone acetate) FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/957/original/fda.pdf?1540331588,BE0003201
F1957,Retisert (Fluocinolone acetate) FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/957/original/fda.pdf?1540331588,BE0008969
F1957,Retisert (Fluocinolone acetate) FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/957/original/fda.pdf?1540331588,BE0004149
F1764,Zanaflex FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/764/original/Zanaflex.pdf?1538681672,BE0004864
F4471,"Canadian monograph, Tizanidine",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/471/original/Canadian_monograph__Tizanidine.pdf?1556041234,BE0003580
F4492,"FDA label, Zanaflex",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/492/original/Zanaflex_FDA_label.pdf?1556057618,BE0003580
F4414,Durlaza FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/414/original/Durlaza_FDA_label.pdf?1555520784,BE0000017
F4399,Memantine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/399/original/Memantine_FDA_label.pdf?1555365027,BE0000311
F4396,Memantine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/396/original/Memantine_FDA_label.pdf?1555364061,BE0004852
F4384,Memantine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/384/original/Memantine_FDA_label.pdf?1555358717,BE0004797
F4384,Memantine FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/384/original/Memantine_FDA_label.pdf?1555358717,BE0009666
F2362,Dalbavancin FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/362/original/021883s003lbl.pdf?1545165340,BE0004826
F2363,Dalbavancin Health Canada Product Monograph,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/363/original/00047194.PDF?1545165370,BE0004826
F4667,FDA Label - Pitavastatin,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/667/original/FDA_Label_-_Pitavastatin.pdf?1564609735,BE0000574
F4361,Fluticasone Furoate (Veramyst) Nasal Spray FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/361/original/Veramyst_FDA_Label.pdf?1555084174,BE0000794
F4364,Fluticasone Furoate (Arnuity Ellipta) FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/364/original/Arnuity_Ellipta_FDA_Label.pdf?1555084343,BE0000794
F4316,"FDA label, Invokana",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/316/original/Invokana_FDA_label.pdf?1554933115,BE0004753
F4313,"Invokana, Canadian monograph",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/313/original/Invokana__Canadian_monograph.pdf?1554913610,BE0004753
F52,"Monograph, Tafinlar",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/052/original/tafinlar_scrip_e.pdf?1525814014,BE0000036
F52,"Monograph, Tafinlar",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/052/original/tafinlar_scrip_e.pdf?1525814014,BE0004757
F52,"Monograph, Tafinlar",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/052/original/tafinlar_scrip_e.pdf?1525814014,BE0004758
F52,"Monograph, Tafinlar",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/052/original/tafinlar_scrip_e.pdf?1525814014,BE0004759
F3562,UKPAR MHRA Prosulf (protamine sulphate) 10mg/ml Solution for Injection Assessment,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/562/original/con272229.pdf?1550683924,BE0000216
F3562,UKPAR MHRA Prosulf (protamine sulphate) 10mg/ml Solution for Injection Assessment,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/562/original/con272229.pdf?1550683924,BE0000280
F134,The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural-associational synapse in chronically stressed rats,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/134/original/tianeptinedoc.pdf?1528746183,BE0000640
F1688,Adynovate FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/688/original/Adynovate_FDA_label.pdf?1538082756,BE0001043
F48,Scientific Committee on Consumer Safety SCCS,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/048/original/22029_methyl_salicylate_clinical2_prea.pdf?1525732838,BE0009546
F2435,Ravulizumab FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/435/original/DB11580.pdf?1545435537,BE0000855
F6,Etafedrine Hydrochloride,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/006/original/Etafedrine.pdf?1524858118,BE0000694
F379,Encorafenib review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/379/original/Encorafenib_Review.pdf?1530720666,BE0000634
F379,Encorafenib review,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/379/original/Encorafenib_Review.pdf?1530720666,BE0001027
F3811,Spravato FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/811/original/Spravato_FDA_label.pdf?1551895045,BE0004956
F4108,Brexanolone FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/108/original/211371lbl.pdf?1553536038,BE0004797
F4063,NHS Evidence Briefing January 2019: Brexanolone for postpartum depression,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/063/original/10557-Brexanolone-for-postpartum-depression-V1.0-JAN2019-NONCONF.pdf?1553196439,BE0004797
F4072,"FDA Briefing Document: New Drug Application 211371/New Drug Application, brexanolone for the Treatment of Postpartum Depression",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/072/original/PDAC_DSaRM-11022018-FDABackgrounder.pdf?1553196664,BE0004797
F4325,Romosozumab FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/325/original/Romosozumab_FDA_Label.pdf?1554996790,BE0009665
F619,FDA advisory committee meeting,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/619/original/20180501-AMDAC-03-SIGA_Backgrounder.pdf?1531754787,BE0009559
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0002131
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0000748
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0002133
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0001203
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0001104
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0000853
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0000852
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0000205
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0000453
F4402,Erdafitinib FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/402/original/212018s000lbl.pdf?1555368103,BE0000369
F3574,"FDA label, Egaten",//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/574/original/Egaten_FDA_label.pdf?1550685235,BE0009630
F4190,Siponimod FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/190/original/Siponimod_FDA_label.pdf?1554146373,BE0002432
F4190,Siponimod FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/190/original/Siponimod_FDA_label.pdf?1554146373,BE0008652
F79,FDA records,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/079/original/1.pdf?1526493192,BE0000329
F131,Pharmacology of estrogens and progestogens: influence of different routes of administration,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/131/original/Kuhl_05__Pharm_Estro_Progest_Climacteric_1313155660.pdf?1528300380,BE0000557
F4355,Fluticasone Propionate (Cutivate) Ointment FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/355/original/Cutivate_FDA_Label.pdf?1555083055,BE0000794
F4358,Fluticasone Propionate (Flonase) Nasal Spray FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/358/original/Flonase_FDA_Label.pdf?1555083126,BE0000794
F4361,Fluticasone Furoate (Veramyst) Nasal Spray FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/361/original/Veramyst_FDA_Label.pdf?1555084174,BE0000794
F4364,Fluticasone Furoate (Arnuity Ellipta) FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/364/original/Arnuity_Ellipta_FDA_Label.pdf?1555084343,BE0000794
F120,Amino Acid Sequence of Phospholipase AZ-a! from the Venom of Crotalus adamanteus,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/120/original/J._Biol._Chem.-1977-Heinrikson-4913-21.pdf?1527281861,BE0000070
F122,THE PHOSPHOLIPASE OF THE VENOM OF THE COTTONMOUTH SNAKE,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/122/original/PiscJ._Biol._Chem.-1945-Fairbairn-633-44.pdf?1527284721,BE0000070
F29,EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/029/original/EMAnet.pdf?1525278584,BE0000384
F138,A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/138/original/COX2.pdf?1529007738,BE0009550
F4289,Mometasone Furoate Twisthaler Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/289/original/Mometasone_Furoate_Twisthaler_Label.pdf?1554757570,BE0000794
F1938,Tegsedi EMA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/938/original/tegsedi-epar-product-information_en.pdf?1539980614,BE0009563
F3685,Turoctocog alfa EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/685/original/novoeight-epar-product-information_en.pdf?1551138300,BE0000364
F3685,Turoctocog alfa EMA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/685/original/novoeight-epar-product-information_en.pdf?1551138300,BE0000216
F4187,Solriamfetol FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/187/original/Solriamfetol_label.pdf?1554136016,BE0000647
F4187,Solriamfetol FDA Label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/187/original/Solriamfetol_label.pdf?1554136016,BE0000486
F4501,Skyrizi FDA label,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/501/original/Skyrizi_FDA_label.pdf?1556127291,BE0008663
F4727,Study Protocol for Phase 1 trial of an RNA interference therapy for acute intermittent porphyria,//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/727/original/protocol_for_phase_1_trial.pdf?1574375964,BE0009790
